Aliphatic N-methylpropargylamines: monoamine oxidase-B inhibitors and antiapoptotic drugs.
Boulton
A A
AA
Neuropsychiatry Research Unit, University of Saskatchewan, Saskatoon, Canada.
Yu
P H
PH
Davis
B A
BA
Paterson
I A
IA
Li
X M
XM
Juorio
A V
AV
Durden
D A
DA
Dyck
L E
LE
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology*; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D011437:Propylamines / Q000493:pharmacokinetics / Q000494:pharmacology; D012642:Selegiline / Q000493:pharmacokinetics / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014018:Tissue Distribution; D014446:Tyrosine 3-Monooxygenase / Q000096:biosynthesis
D007527:Isoenzymes; D008996:Monoamine Oxidase Inhibitors; D011437:Propylamines; C094098:N-2-hexyl-N-methylpropargylamine; D012642:Selegiline; D014446:Tyrosine 3-Monooxygenase; D008995:Monoamine Oxidase